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 Highlights 
• Rheumatoid arthritis (RA) affects 1% of the population and is highly debilitating. There 
is a pressing need to seek alternative therapeutic strategies as well as optimise those 
available at present. 
 
• RA is ~65% heritable, yet the concordance rate between monozygotic twins is lower 
than expected at 20 - 30%, indicating a substantive role of other factors in RA 
pathogenesis. 
 
• Studies have shown that the gut, oral and lung microbiome is different in treatment 
naïve and established RA patients compared to controls. 
 
•  Current findings suggest an important influence of host genetics to the oral and gut 
microbiome, which may contribute to RA via the host immune system. 
 
 
• The microbiome may provide a new avenue of therapeutic options in RA. 
 
• Associations described thus far are confounded by host genetics so studies need to 
take account of this when describing the influence of the microbiome in RA. 
  
 Abstract 
Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterised by painful 
synovium inflammation, bony erosions, immune activation and the circulation of 
autoantibodies. Despite recent advances in therapeutics enabling disease suppression, there 
is a considerable demand for alternative therapeutic strategies as well as optimising those 
available at present. The relatively low concordance rate between monozygotic twins, 20 - 
30% contrasts with heritability estimates of ~65%, indicating a substantive role of other risk 
factors in RA pathogenesis. There is established evidence that RA has an infective 
component to its aetiology. More recently, differences in the commensal microbiota in RA 
compared to controls have been identified. Studies have shown that the gut, oral and lung 
microbiota is different in new onset treatment naïve, and established RA patients, compared 
to controls. Key taxonomic associations are an increase in abundance of Porphyromonas 
gingivalis and Prevotella copri in RA patients, compared to healthy controls. Host genetics 
may provide the link between disease and the microbiome. Genetic influence may be 
mediated by the host immune system; a differential response to RA associated taxa is 
suggested. The gut microbiome contains elements which are as much as 30% heritable. A 
better understanding of the influence of host genetics will shed light onto the role of the 
microbiome in RA. Here we review the role of the microbiome in RA through the lens of host 
genetics, and consider future research areas addressing microbiome study design and 
bioinformatics approaches. 
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 Graphical Abstract 
 
Putative interactions mediating the link between host genetic factors, the gut and oral microbiome and rheumatoid arthritis. 
 
Introduction 
Rheumatoid arthritis (RA) is a chronic multisystem autoimmune condition, characterised by 
painful swelling of the synovial joints bone and tendon damage. RA affects almost 1% of the 
population and is highly debilitating, with a profound effect on life quality in both young and 
elderly people.  It has a significant economic impact on society partly through loss of working 
ability [1]. Despite considerable recent advances in therapeutics enabling disease 
suppression, there is still a sizeable minority of patients where drug therapies are ineffective 
or poorly tolerated, with potential serious adverse effects and the need for regular blood 
monitoring to early detect these [2]. Thus, there is a considerable demand for alternative 
therapeutic strategies as well as optimising those available at present. 
 
RA is a common complex disease derived from the interplay between genetic and 
environmental factors [3,4]. Known risk factors include periodontal disease [5],  smoking [4], 
diet [6] and hormone fluctuation – the disease is more prevalent in women [5-7]. The 
relatively low concordance rate between monozygotic twins, at 20 - 30%, contrasts with high 
heritability estimates of ~65% [8], indicating a substantive role of other risk factors in RA 
pathogenesis in genetically susceptible individuals [9]. There is early evidence of epigenetic 
influence [10] and a longstanding appreciation of the possible role of infection as triggering 
the immune activity [11]. Despite genome-wide association studies (GWAS) and GWAS 
meta-analyses of increasingly large samples, the 349 variants identified for RA account for 
less than a third of the estimated heritability – a common finding in complex traits. This 
“missing heritability”, i.e. the inability to account for the proportion of phenotypic variance 
contributed by genetic factors – may be due to (i) structural variation (such as copy number 
variations-CNVs), (ii) by rare variants, or (iii) by environmental factors which are influenced 
by host genetics.  
 
RA presents disease subsets, the clearest of which are characterised by the presence or 
absence of auto-antibodies – seropositive and seronegative RA respectively. There is a 
genetic aetiological difference, with seropositive RA being secondary to the human leukocyte 
antigen (HLA) DRB1 (encoding the major histocompatibility complex -MHC) – the shared 
epitope. Heritability differs by disease subtype, and is estimated at around 65 and 30 percent 
for seropositive and seronegative disease, respectively.  Seropositive disease is much more 
clearly defined so will be the focus of this review. Symptoms develop in the later stages of 
immune dysfunction following a prolonged period of autoimmunity which, in seropositive RA, 
is marked by a surge in circulation of auto-antibodies – rheumatoid factor and anti-
citrullinated protein [6]. Even in seronegative RA the onset of symptoms is typically preceded 
by years, or even decades, of increased levels of circulating pro-inflammatory cytokines [1]. 
This has prompted the theory that an environmental factor triggers disease progression. The 
microbiome, and particularly the alimentary tract microbiome, offers one such candidate 
mechanism [12].  
 
The microbiome is the collective genome of the vast community of commensal micro-
organisms - predominantly bacteria, which inhabit epithelial surfaces [5], blood [13] and 
tissue [14]. These organisms form a vast symbiotic community, the importance of which in 
physiological function has only recently been uncovered, secondary to availability of next 
generation sequencing [15]. The microbiome – the bulk of which is contained within the 
intestine [16], constitutes a substantial antigenic load and is essential for normal immune 
development in the neonate, with a life-long role in immune education [17]. It is therefore 
highly plausible that it has a role – possibly very early in life – in the promotion of subsequent 
autoimmunity. Further, the microbiome represents a unique physiological interface - a 
signalling hub, integrating environmental inputs with genetic and immune signals [15].  
 
There is substantial diversity in the microbiome amongst the population [18], and individual 
differences may be influenced by diet [19], host genetics [20], age [21], host general health 
[22], antibiotic exposure and bowel habit. Specific variations associate with diseases, and to 
date the microbiome has been implicated in a vast array of medical conditions, including 
inflammatory bowel disease [23], cancer [24] and obesity [25]. The gut microbiome is the 
most influential, and are a number of ways the it can be altered therapeutically: pro or pre-
biotics, diet and faecal microbiota transplantation, raising the possibility of hitherto 
unexplored treatment options.   
 
Studies suggest that the microbiome and particularly the gut microbiome is different in 
people with RA and may be implicated in the pathogenesis of RA [18,26]. However, the 
many cross- sectional observations are challenging to place in the context of the temporal 
evolution of autoimmune disease which evolves over decades and is usually treated as soon 
as symptoms manifest and the diagnosis is confirmed. In RA there is a gradual transition to a 
pro-inflammatory phenotype, facilitating the development of disease in genetically 
susceptible individuals. There may be a bi-directional relationship between RA pathogenesis 
and the microbiome, in which the microbiome may contribute to the pro-inflammatory 
phenotype during the propagation stage of autoimmunity. To date nine epidemiological 
studies [5,18,26,35,44,117-120] have shown alterations in the microbiome in both treatment 
naïve - excluding an influence of drug effects on the microbiome therefore, and established 
RA patients, with mechanisms demonstrated in mouse and cellular models. Taxa 
associations replicate across studies to a greater degree than is usually shown in disease 
specific microbiome studies, as shown by a recent meta-analysis [27].  
 
Whilst host genetic factors clearly predispose to RA they may also mediate in part the 
interaction between the microbiome and RA pathogenesis.  The gut microbiome itself 
contains elements which are as much as 30% heritable [20]. Given that the identified genetic 
risk loci in RA are associated with immune function, it is feasible that risk genotypes for RA 
act in part via the microbiome. Therefore, the microbiome may explain part of the 
aforementioned missing heritability in RA; microbes produce a range of enzymes, chemicals, 
hormones and vitamins that may interact with host metabolism, contributing to as much as 
one third of the metabolites identifiable in human blood [28].  
 
In this review, the evidence for the role of the gut microbiome in RA will be evaluated, 
through the lens of host genetic factors. An overview of the genetic aetiology of RA will be 
given, followed by an evaluation of the evidence for the role of the microbiome in RA, and 
potential links between host genetics and the microbiome in RA. Areas for further research 
will then be considered. 
 
Genetic Aetiology of Rheumatoid Arthritis 
In the past few years large-scale human GWAS of RA having over n=100,000 participants 
have led to the identification of a substantial number of associated genetic loci. Several 
common pathways associated with prevalence, severity and progression of rheumatologic 
disease have been identified. Forty GWAS found a total of 349 SNPs across all 
chromosomes (Figure 1), that are associated with RA (Table 1), and 100 SNPs have been 
replicated on meta-analysis. These studies have revealed that the dominant risk loci in RA 
are, unsurprisingly for autoimmune disease, located in the MHC region[8] on 6p21.3 and 
these account for the major proportion of the current heritability explained in RA. Classically, 
this MHC association is explained mechanistically by the ‘shared epitope’ hypothesis [8]. The 
HLA-DRB1 shared epitope alleles - *04:01, *04:04, *04:05, *04:08, *10:01, *01:01 and *01:02 
encode for amino acids in position 70 to 74 within the binding site of MHC-II; they therefore 
influence the host response to extracellular immune ligands.  The shared epitope alleles are 
associated with increased susceptibility to RA, and particularly anti-citrullinated protein 
antibody (ACPA) positive RA; carriers of these alleles have enhanced immune response to 
citrullinated proteins. Heterozygosity for human leukocyte alleles (HLA) may confer greater 
risk of disease due to a wider auto-antigen repertoire of carriers. MHC variants have wider 
impact than the classic shared epitope hypothesis as this region is characterised by 
extremely dense and diverse sequence variations, and contains around 250 genes encoding 
numerous immune molecules in addition to HLA such as complement factors, cytokines and 
other proteins involved in antigen processing. The complexity of genomic control 
mechanisms across this region is enormous and only just being unravelled [8,29]. 
 
Over 100 associated non-MHC loci have been identified through GWAS meta-analyses [29]. 
These include variants at the gene encoding protein tyrosine phosphatase, non-receptor type 
22 (PTPN22) which functions as a negative regulator of T cell receptors [30], peptidylarginine 
deiminase 4 (PADI4) which encodes enzymes active in protein citrullination [31], signal 
transducer and activator of transcription 4 (STAT4) which encodes a transcription factor 
specific for T cell maturation [32], and TNFAIP3 which encodes tumour necrosis factor alpha 
(TNF) [33]. These protein coding genes together influence the immune response  and 
collectively promote a shift to a pro-inflammatory phenotype and increased sensitivity to 
immune stimulation [34]. Walsh and colleagues characterised the role of protein coding RA 
associated SNPs and showed involvement in both the innate and adaptive immune systems, 
which would support a shift to a pro-inflammatory phenotype: jak-STAT signalling pathway; 
IL-12 mediated signalling; endocytosis; T cell signal transduction; signalling downstream of 
interleukins and T cell receptors; cytokine signalling; cell adhesion molecules and B 
lymphocyte cell surface molecules. In keeping with most common complex trait GWAS 
results, the associated SNPs largely do not reside in protein coding regions, and may act 
distally with unidentified genes. Non-coding variants are likely to have a role in regulation of 
immune mediating gene expression [34].  
 
However, as with other complex traits, a full understanding of genetic risk in RA has proved 
evasive; known risk loci explain only 15% of the estimated heritability, indicating that 
numerous associations are yet to be discovered [8]. This is perhaps because GWA studies 
were designed to detect common genetic loci associated with disease, yet genetic risk in RA 
may be mostly driven by rare variants, with a minor allele frequency (MAF) of less than 0.05 
giving accumulated aetiological effect. Research methods must accommodate the polygenic 
nature of RA, with variable genetic architecture between individuals who may possess 
numerous RA associated variants of modest effect. Polygenic risk scores (PRS) provide a 
weighted genetic risk score for individuals, combining individual genotype data with the 
strength of the disease association for each risk variant. Association of PRS with phenotypes 
can be modelled, offering an effective option for RA research, and provides a surrogate 
model of RA allowing examination of the host genetic factors without the confounding 
influence of the disease or its treatment. 
  
Figure 1. Genetic Associations with rheumatoid arthritis shown to date. HLA type (highlighted) shows 
direct mechanistic links with the oral and gut microbiome.  
 Gut Microbiome in RA 
Studies have shown that the gut [18], oral [5], and to a lesser extent, lung [35] microbiomes 
have been implicated in RA when comparing RA patients to healthy controls (see Table 2). 
Whether this association is causal has not yet been established. The gut microbiome has 
been the focus of the RA microbiome link -  it constitutes over 80% of the total microbial 
biomass, with the closest links to the immune system. Nine studies have reported changes in 
diversity and taxa present in the microbiome of RA patients compared to age, gender and 
weight matched controls. Whilst lower gut microbiome diversity is known to be a generalised 
feature of disease [22], the taxonomic and bacterial gene associations with RA are of greater 
etiological interest. However, there are discrepancies in these associations across the 
published studies. A link with host genotype, mediated by HLA type in addition to a more 
general pro-inflammatory genetic predisposition in RA, is suggested. 
 
Prevotella copri (P.copri) is the most frequently reported bacterial species showing variation 
of abundance between RA patients and unaffected controls. However, P.copri is associated 
with other inflammatory conditions including metabolic syndrome, insulin resistance, type II 
diabetes and atherosclerosis [36], in addition to RA [37,38], and may thrive relative to other 
bacteria within an inflammatory host environment [39]. Therefore, individuals with RA risk 
genotypes, leading to pro-inflammatory immune phenotype, may potentially constitute an 
ecological niche.  This could be in addition to a possible role in disease causation, but needs 
to be borne in mind when assessing association studies.    
 
Scher and collaborators performed 16s analysis on faecal samples from 144 participants – 
new onset RA (n=44), chronic RA (n=26), psoriatic arthritis (n=16) and healthy controls 
(n=28). They found that in the gut microbiome P.copri was most abundant in patients with 
new-onset RA compared with those with chronic treated RA (p<0.01), psoriatic arthritis 
(p<0.01) or healthy controls (p<0.01) [26]. This important finding was partially replicated in 
the study below by Zhang  and co-workers [18].  Higher abundance of P. copri in the gut 
microbiome is a characteristic on new-onset RA, they suggest, in which inflammation is 
relatively unabated by medication. Increased abundance of P.copri  in new onset RA patients 
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correlated with a decrease of of Bacteroides fragilis (B. fragilis), an important regulator of 
regulatory T cell (Treg) function. Tregs function in the establishment and maintenance of 
immune tolerance. This therefore suggested that P.copri may influence RA pathogenesis via 
indirect suppression of Tregs via the lower relative abundance of B. fragilis in these patients, 
but might equally be explained by the inflammatory milieu hypothesis. Genotyping of new 
onset RA patients showed that this increase was associated with HLA DRB1 4 shared 
epitope (SE) genotype [26]. This work replicated previous findings which - whilst not directly 
linked to RA, have linked  host genetics with Prevotella and other taxa - Pasteurellaceae, and 
Leptotrichia, which were associated with SNPs encoding for ATP-binding cassettes, protein 
synthesis, cell division, and tumour suppression [40]. Similar association of Prevotella with 
HLA has been shown in mice [41]. These findings warrant further investigation. We know that 
the host genome impacts the microbiome: if microbiome changes are also mediated by 
genotype we could speculate that microbiome alteration appears before clinical disease 
manifests, and perhaps lies on the causal pathway to RA. 
 
Zhang and collaborators  undertook shotgun metagenomic sequencing on 212 faecal 
samples from 3 groups: 77 untreated RA patients matched with 80 unrelated healthy 
controls, 17 untreated RA patients matched with 17 healthy related controls, and a third 
group of 21 DMARD-treated RA patients [18]. To delineate features of the RA-associated gut 
microbiome, they identified 117,219 gene markers that were differentially enriched in RA 
patients versus controls and clustered the genes into metagenomic linkage groups (MLGs) 
on the basis of their correlated abundance variation among samples. They identified 88 
MLGs that contained at least 100 genes, which separated RA-enriched and control-enriched 
MLGs. Of the MLGs comprising greater than 100 genes, RA was associated with MLGs 
containing Lactobacillus salivaris, Clostridium asparagiforme, Gordonibacter pamelaeae, 
Eggerthella lenta, Lachnospiraceae bacterium, Bifidobacterium dentium, Lactobacillus spp 
and Ruminococcus lactaris. The control group showed a negative correlation with 
Haemophilus spp., K. pneumoniae and Bacteroides spp., B.bifidum and R.lactaris [18], 
suggesting an antagonistic or mutually exclusive relationship and highlighting the 
interdependency of species especially when measured as relative abundances [42,43].  
None of the MLGs containing 100 or more genes contained Prevotella, however when the 
authors compared the MLGs with the NCBI Prevotella reference genome, there was a trend 
towards increased abundance of P.copri as a function of RA duration in the first year of 
disease onset [18]. Prevotella may therefore be a particularly variable taxon, where bacterial 
genes and associated functions vary to a greater extent than in other taxa.  
 
Zhang and collaborators also showed that treatment with RA therapeutics – disease 
modifying antirheumatic drugs (DMARDs), in which the inflammatory response is abated, 
was associated with a “normalised” more diverse microbiome; this is in contrast to the 
general observation that medication intake associates with reduced diversity [22].  This effect 
was observed for Methotrexate, as the most widely prescribed DMARD.  Other drugs used 
by the cohort – Leflunomide, Prednisolone, Hydroxychloroquine and Etanercept were not 
prescribed to enough participants to power analysis. Further study of specific DMARDS and 
at multiple time-points is needed. However, this supports the hypothesis that microbiome 
changes in RA are driven at least in part by systemic inflammation.  
 
The above studies accounted for body mass index (BMI) and sex, which have known 
associations with gut microbiota and these factors showed no association with microbiota 
profile. The reported associations thus far are therefore unlikely to be driven by diet or 
obesity. However an influence of diet on RA via the microbiome is possible, and warrants 
further study. Similarly, whilst gender is controlled for , the independent role of gender in the 
link between the microbiome and RA has not been investigated. However an influence is 
feasible, via genetic differences (some associated SNPs lie on the sex chromosomes), diet, 
hormone fluctuation.  
 
Prevotella copri is therefore the key candidate taxon in RA, with a finding of increased 
abundance in RA patients compared to controls replicated across 4 of 7 published 
epidemiological studies of the microbiome using next generation sequencing [5,18,26,44]. 
Moreover, P.copri  was shown to mediate immune activation with 24% of RA patients having 
IgA or IgG responses to Pc-p27, an HLA-DR presented P.copri peptide, compared to 2% in 
healthy controls [37]. Further investigating the specificity of P.copri in immune activation in 
RA,  P.gingivalis (shown previously to increase in RA), Bacteroides fragilis (shown previously 
to decrease in RA) and Escherechia coli (not previously implicated in RA), were shown to 
have no immune memory. While suggestive, the associations in human RA patients to date 
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has been unable to elucidate whether the Prevotella-RA association is driven by host 
inflammation, or is in some part causal.   
 
Mouse studies demonstrated that the Prevotellecae enriched microbiome of RA patients, 
when transferred to arthritis susceptible SKG mice, increases sensitivity to arthritis via 
activation of autoreactive T cells in the intestine. T cell differentiation and an increase in 
autoreactive T cells is a known driver of RA pathogenesis. Faeces from 3 RA patients and 3 
healthy controls were analysed for microbiome composition, before transfer to SKG mice. 
After 20 weeks of colonisation, the total number of CD4+ T cells and the number of pro-
inflammatory IL-17 producing CD4+ T cells in the large intestine were increased in RA-SKG 
mice compared with HC-SKG mice [45]. It remains unclear whether P. Copri is robustly 
associated with or actually causative in RA [16,26,36,37,39,46]. One explanation for the 
conflicting findings is that Prevotella is a particularly variable taxon, with different genes and 
biological characteristics even at the strain level, leading to different results in relation to 
P.copri  in RA. The jury is therefore still out on the relevance of prevotella to RA 
pathogenesis, though current findings are promising. Associations with other taxa show 
weaker evidence, with lower reproducibility across studies. Overall, taxa associations, whilst 
useful, can only go some way to indicating the genomic functional capacity of the 
microbiome. Further work, especially incorporating metagenomics analysis of genetic 
capability of a microbiome will be critical to provide clarity. 
 
The Oral  Microbiome in RA 
Shared Epitope Interaction with the Oral Microbiome 
One of the earliest links between commensal microbiota and RA pathogenesis was shown in 
the oral microbiome. Individuals with RA had a higher incidence of periodontal disease – 
linked to oral microbiome dysbiosis, and that periodontal disease treatment improved RA 
symptoms [5,47,48]. This is highly plausible because of the known interaction between the 
oral microbiome, co-occurring with periodontal disease and progression to clinical RA, 
secondary to shared epitope HLA-DRB1 genotype. The oral and lung mucosa have been 
proposed to be the primary sites of protein citrullination in RA, via oral microbiome changes 
[5] and smoking status[4], respectively. The host immune response to citrullinated proteins is 
mediated by the shared epitope, which encodes the binding motif of MHC II. Variation in 
MHCII results in altered immune response to extracellular antigens, and carriers of the 
shared epitope have enhanced response to citrullinated proteins, and subsequent increase in 
ACPA. RA patients have been shown to have a 5.7 fold increased risk of periodontal disease 
(95% CI 2.35 - 13.84) in a stepwise logistic regression, including other predictors of 
periodontal disease – age, education, smoking, alcohol consumption level and BMI, only age 
and RA remained as significant predictors [48]. The oral microbiome may therefore be the 
primary mediator of protein citrullination, having greater influence even than smoking. 
 
Bacterial taxa associated with RA may provide the mechanistic link for this association. 
Porphyromonas gingivalis, is an oral commensal found in increased in abundance in RA 
patients [5,18], and it is active in citrullination of host proteins – providing a precursor step for 
production of specific antibodies [18], and mediating synovial inflammation [46]. Further, 
Porphyromonas gingivalis has evolved to alter its microenvironment within the oral 
microbiome by modulating the host TLR2 pathway to uncouple bacterial clearance from 
inflammation and therefore exacerbate the microbial ecological niche [49]. 
 
 
 
 
 
 
 
 
 
Figure 2. Interaction between host genetics and the oral microbiome in RA. Mechanism by which HLA-DRB1 genotype 
and Porphyromonas gingivalis in the oral microbiota can interact to contribute to RA pathology, via upregulation of 
circulating ACPA.  
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The caspase recruitment domain family member 9 gene (CARD9) which encodes an adaptor 
protein that integrates signals downstream of pattern recognition receptors [50], has been 
shown to be important in mouse models of arthritis [51].  Using two CARD9 knockout mouse 
models, with neutrophil-specific deletion, and wild-type control mice, the effect of CARD9 
deficiency was investigated using the KBXN serum transfer model. Clinical signs of arthritis 
were quantified in CARD9 knockout mice which showed significant ankle thickening 
(P=0.0047) and reduced grip strength (P= 2×10−4), compared to wild-type mice [51]. To date, 
no GWAS has shown CARD9 to be a risk allele for RA in humans, but it is an interesting 
model gene which has relevance in other autoimmune diseases including  inflammatory 
bowel disease (IBD)[52], ankylosing spondylitis [53], IgA nephropathy[50] and colitis[54]. 
 
CARD9 knockout mice exhibited downregulation in IL-22 signalling, resulting in impaired 
recovery from colitis when compared to wild-type mice. Analysis of the gut microbiota 
revealed no difference in beta diversity, but highlighted a decrease in abundance of 
Adlercreutzia (genus), Actinobacteria (phylum), and Lactobacillus reuteri (species), indicating 
an in influence of CARD9 genotype on the gut microbiome in these mice. Transfer of the 
CARD9 knockout mouse microbiota to germ-free wild type mice resulted in an exacerbation 
of colitis, to a similar degree as CARD9 knock out mice – suggesting a causative, rather than 
correlative, relationship between the microbiome and IL-22 mediated inflammation.  
 
The gut microbiota of CARD9 knockout mice showed impaired catabolism of tryptophan, a 
downstream effect of which is IL-22 production, and this is suggested to be a key underlying 
mechanism [54]. IL-22 is a Th17 cytokine, which in addition to an integral role in maintaining 
the gut barrier, has diverse functions in balance with pro-inflammatory IL-17, which vary 
according to tissue type and duration of expression. IL-22 promotes wound healing and 
tissue homeostasis acutely, however chronic unabated expression is associated with a 
number of inflammatory conditions. The role of neutrophils in RA has been highlighted in a 
recent review [55]. 
 
 
General Mechanisms Linking the Microbiome and RA  
The accumulating evidence implicating the microbiome in RA pathogenesis has prompted 
investigation into the underlying mechanisms, of which a number have been proposed: 
molecular mimicry; outer membrane vesicles (OMVs); T cell differentiation; epigenetic 
modification; immune priming. 
The gut microbiome produces a variety of metabolites, including small organic acids, bile 
acids, vitamins, choline metabolites, and lipids[64,65]. The plethora of small molecules 
produced, alongside 
microbial cellular 
components, share some 
structural similarity with 
the host. Such molecular 
mimicry refers to the 
similarity of bacterial 
peptides of RA 
associated antigens, or to 
affinity of bacterial 
peptides to host 
receptors [18]. Molecules 
associated with bacterial 
cell to cell communication 
– quorum sensing, may 
also influence cellular 
processes within the 
host. 
 
For example, P.gingivalis, which is found in increased abundance in the oral microbiome in 
RA (and also found in the gut) shares 82% homology of α-enolase with human α-enolase at 
the immunodominant region. Human antibodies against bacterial elonase also recognise 
human α-enolase, promoting further antibody production [66]. In RA patients, levels of anti-
citrullinated human α-enolase antibodies and bacterial α-enolase are shown to correlate with 
one another (R2=0.0803, P<0.0001) [67].  
Box 1. RA as a Model of Ageing – Potential role of epigenetics and the microbiome 
 
Patients with RA prematurely show a number of features of an aged immune 
system, and RA has therefore been proposed as a model of immune ageing. There 
are a wide range of disruptions to the delicate balance within the immune system 
which occur with ageing, mediated in part by epigenetic changes, and having 
potential impact on the host response to the microbiome [56]. Key changes are 
compromising of epithelial layer integrity through disruption of tight junctions [57],  
and immune-senescence [56,58], which may be secondary to a reduction in 
telomerase [56,59]. Loss of function of telomerase in lymphocytes, leads to loss of 
the unique ability of these cells to elongate telomeres, a consequence of which is 
cellular senescence [60]. A second pathway, independent of telomerase, is 
senescence secondary to genomic instability and prolonged activation of the DNA 
damage response (DDR). The DDR pathway has been shown to be particularly 
important in peripheral blood mononuclear cells (PBMC) and both naïve and 
memory CD4+ T cells, but not neutrophils, in RA patients [61] . Cellular senescence 
of T cells results in clonal expansion of sets of naïve T cells. Early in the onset of 
RA there is clonal expansion of both CD4+ T and C8+ T cells. This is accompanied 
by a relative lack of expression of co-stimulatory molecules from memory T cells, 
particularly CD28, which is required for efficient T-cell activation and proliferation. A 
lower level of CD28 is associated with a pro-inflammatory phenotype, increased 
cytotoxicity and increased rates of tissue infiltration [56,61]. Other immune changes 
in both ageing and RA include altered patterns of DNA methylation and therefore 
gene expression, chromatin remodelling, failure of protein homeostasis, altered 
nutrient sensing and mitochondrial dysfunction [56]. There are therefore diverse 
differences, having far reaching physiological effects. Animal models have been 
used to determine which intracellular pathways are most implicated in ageing, and 
a key identified difference is defective transgenic growth factor β (TGFβ) signalling. 
More specifically, downstream, SMAD3 signalling has been shown to promote 
cartilage damage [62]. The microbiome may contribute to these shifts in immune 
phenotype; expansion of the pro-inflammatory cytokine milieu in the host is 
suggested as the primary mechanism of immune ageing [63]. 
 
 Molecular mimicry also promotes autoreactive T cell activation and proliferation. E. coli heat 
shock protein DnaJ contains a QKRAA motif that is also present in the HLA-DRB1 shared 
epitopes [66]. DnaJ strongly activated RA synovial T cells which had passed the positive 
selection in the thymus through weak binding with the corresponding HLA epitopes [68].  
 
 
 
Figure 3. Summary of mechanisms by which molecular mimicry of the gut microbiota, and 
CARD9 genotype can contribute to systemic inflammation.  
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OMVs produced by gram negative bacteria modify the local environment to facilitate bacterial 
proliferation, signal between bacterial species and have been shown to communicate directly 
with host cells [69–71]. In the host, OMVs affect intracellular signalling [71] and overall 
metabolic profile [72]. Thus, investigation of OMVs may be an important step in 
understanding the link between the microbiome and host. Interestingly, OMVs of pathogenic 
and non-pathogenic strains of the same species manifest differing metabolic associations 
[73]. 
The anti-inflammatory influence of the microbiome may also play a role in RA. Dietary poly- 
and oligosaccharides resistant to upper gut digestion pass to the distal gut where they serve 
as a source of carbon and energy for gut bacteria. Through fermentative reactions, the gut 
microbiota can metabolize complex carbohydrates to produce small organic acids, the 
majority of which are comprised of the short-chain fatty acids (SCFAs) -acetate, propionate, 
and butyrate.  
SCFAs, and butyrate in particular may influence host physiology, as these metabolites are 
linked to expansion of Tregs, and a protective anti-inflammatory role is proposed for them. 
 
Considerations for Future Studies 
Limitations of Mouse Models in Microbiome Research 
Mouse models are widely used in microbiome research and can be informative – particularly 
when used to understand or replicate a specific mechanism. However, there are key 
differences between mouse and human microbiome physiology which are seldom discussed. 
The mouse and human genome are separated by more than 90 million years of evolution, 
during which there has been substantial change in the immune system and its regulation. 
The GI tract anatomy and physiology of the mouse is markedly different to that of humans, 
and in particular the presence of the glandular forestomach in the mouse, with its biofilm of 
lactobacillus spp, and mucus trap where mucus and bacteria are recycled to the cecum. 
There are differences in morphology and retention time, and mice engage in coprophagy, 
and transfer gut microbiota between each other when housed together. These factors confer 
differences in mouse vs human microbiome, and in physiological response to bacteria. The 
presence of taxonomic differences in the murine versus human microbiome may have 
resulted in over-interpretation of the clinical relevance of findings shown in mouse models. 
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There are numerous references to the importance of segmented filamentous bacteria (SFB) 
within the RA microbiome literature, since it was shown that introduction of SFB in a mouse 
model regulated TH17 differentiation [74].  This is often cited as convincing evidence of the 
microbiome inducing T cell differentiation. However, SFB, also known as Candidatus 
arthromitus within the Greengenes database, are usually only present in humans during early 
life, and so the relevance in human RA is at best unclear, and whether other species have 
comparable effect in humans remains open to debate. 
 
In murine models of 
inflammatory arthritis 
germ free mice fail to 
develop the diseased 
state[45], in contrast to 
microbiota exposed 
arthritis model mice 
which ubiquitously 
develop symptoms, 
suggesting an integral 
role in immune 
development of 
commensal microbiota 
[75]. Germ free mice 
exhibit immune 
differences, culminating 
in a much-dampened 
immune response. 
Therefore, it is unsurprising that these mice do not develop inflammatory or autoimmune 
disease. The relative disease progression of mice gavaged with RA-associated microbiota 
compared to germ free mice should therefore be interpreted with caution and comparison to 
mice with a different (“healthy”) humanised microbiome might be preferable. 
 
Box 2. Developing Bioinformatic Approaches for Microbiome Data 
 
Next generation sequencing has provided the means to access a wealth of information relating to 
commensal bacterial communities, however there are a wide variety of technological and analytical 
methods available – it is important to understand the benefits and limitations of the most frequently used 
methods: operational taxonomic units (OTUs), amplicon sequence variants (ASVs) and metagenomics. 
The most frequently used approach in microbiome sequencing is16s. This refers to sequencing of 
bacterial ribosomal RNA (rRNA) gene, using methods which take advantage of the particular structure of 
the 16s ribosomal component [76]. 16s rRNA is a component of 30s small subunit of prokaryotic 
ribosome, of which there are 9 variable regions – varying between phylogenies, which are each flanked 
by highly conserved regions.  DNA is first extracted from the biological sample. Following this, primers 
linked to an identifier barcode, specific to highly conserved binding sites, provide a template for PCR 
amplification. An alternative approach is whole genome metagenomic sequencing, this is more costly but 
provides important additional information - particularly bacterial genes present [77]. Classically, following 
sequencing data are assigned to operational taxonomic units (OTUs), in which sequences are binned 
(grouped) together according to a similarity threshold. There are a number of alternative methods picking 
OTUs – open reference, closed reference or de novo approaches can be taken. These approaches differ 
in the use of a database (e.g Greengenes or SILVA) as a reference when performing clustering. Within 
these approaches, a number of algorithms may be used.  The de-novo approach, whilst computationally 
less efficient (requiring pair-wise comparisons between sequence reads), has been shown to produce 
OTUs that are more representative of functional microbial units [78]. The OTUs in conjunction with a 
genome reference database are then used to assign taxonomy, determining which bacteria are present 
in the samples. Amplicon Sequence Variants (ASVs), also known as exact sequence variants, offer an 
alternative approach to OTUs, and hold a number of advantages over traditional OTU methods[79]. 
Briefly, ASVs are generated by using the error rate within the dataset to infer true biological sequences, 
and group identical sequences exactly, rather than to a similarity threshold. There are a number of 
advantages to this approach, demonstrated by increased sensitivity and specificity of ASVs compared to 
the most often used methods of OTU generation [79,80]. ASVs overcome other key limitations of OTUs 
and allow for valid direct comparability between datasets[80], and  accurate taxonomic assignment at the 
species level [79]. The direct comparability between datasets, in conjunction with correcting for ‘batch 
effects’ on analysis could allow for the merging of multiple RA microbiome datasets, which could shed 
light on the conflicting taxa associations reported. 16s analysis is inferior however to metagenomic 
sequencing, which although at greater expense, provides key additional information – genes present and 
full species assignment, allowing for much richer functional analysis. Moving forward, ASVs show 
exciting potential in 16s analysis, and could advance understanding of the role of the microbiome in RA, 
both through analysis of existing datasets and through use in future studies. 
 
Large-scale human observational studies in RA are underway, including the use of family- 
and twin studies to unpick the contributions of host genetics and microbiome.  In addition, 
population based studies linked to health records are now incorporating microbiome 
assessment, which will allow the interrogation of the microbiome prior to diagnosis 
retrospectively.  Studies in at risk groups, such as those at genetic risk, those with 
periodontal disease and smokers may provide insight as to the temporal relationship 
between microbiome alterations and altered inflammation. Low-risk interventional studies in 
humans are around the corner and will be needed to ascertain whether effects are relevant 
to the development of RA or bystanders of an altered milieu. 
 
Sample Collection, Storage and Processing 
In most studies, the means of measurement of the gut microbiome is the microbial 
composition of stool samples.  Although the faecal microbiome provides a useful indicator of 
the gut microbiome, they are of course distinct entities with differences starting in the 
mucosal layer, epithelium, lumen in small intestine through to stool. In studies of the gut 
microbiome therefore, a useful additional measure may be the use of colonic biopsy. 
Differences in sample storage, and particularly the immediacy of freezing sample, 
temperature on freezing or use of an RNA inhibitor with sample add to the difficulty of 
comparing results across studies. This is difficult to address, but newer bioinformatic 
approaches as described above may go some way towards a solution. 
 
Therapeutic Modulation of the Microbiome in RA 
Current understanding of the microbiome in RA does not feasibly allow development of 
therapeutics at this stage. Moving forward, there is potential in the future for the microbiome 
to be useful as a target in RA, either as a target for modulation, or as a biomarker of potential 
for disease progression in arthralgia. Modulation may be possible via pro-biotics comprised 
of bacteria with beneficial functions, or precision editing, for example through use of 
bacteriophages. Given that RA seems to associate more with abundance of pathogenic 
bacteria, as opposed to a deficit in beneficial bacteria, precision editing of the microbiome 
may be a more likely option, for example through use of bacteriophages.  
Commented [WP7]: Reviewer point 3: 
It wasn't clear if there is any data on patients given antibiotics 
or specific probiotics with respect to course of disease? 
 
Current understanding of the RA microbiome is at an early stage, and as would be expected 
the pre-emptive trials of general use, non-RA specific probiotics have been inconclusive [12]. 
Use of the microbiome as a biomarker, to detect those at greater risk of progression from 
arthralgia to RA, is also feasible – if microbiome changes are present before onset of 
disease, and would allow for earlier intervention in these patients to improve clinical outcome 
[3].  
Conclusions 
There are compelling associations between the microbiome and RA, although the current 
evidence is far from conclusive that the microbiome causes RA. Strategic future studies 
replicating previous findings and addressing the gaps in the current knowledge are required. 
In particular it will be important to determine the influence of disease modifying RA 
medication on the microbiome. Host genetics may provide the link between the microbiome 
and RA and is a particular challenge to address, although current findings are suggestive of 
an important influence which may be mediated by the host immune system which could be 
ameliorated. A better understanding of whether associations described thus far are 
confounded by host genetics will shed further light on the role of the microbiome in 
rheumatoid arthritis.  
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